Synthesis and biological characterisation of [3H]BBL454, a new CCK2 selective radiolabelled agonist displaying original pharmacological properties.

[1]  B. Roques,et al.  Development of new potent agonists able to interact with two postulated subsites of the cholecystokinin CCK-B receptor , 1997, Letters in Peptide Science.

[2]  A. Puech,et al.  Failure of CCK receptor ligands to modify anxiety-related behavioural suppression in an operant conflict paradigm in rats , 1995, Psychopharmacology.

[3]  B. Maigret,et al.  Replacement of glycine with dicarbonyl and related moieties in analogues of the C-terminal pentapeptide of cholecystokinin: CCK(2) agonists displaying a novel binding mode. , 2000, Journal of medicinal chemistry.

[4]  J. Crawley,et al.  International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. , 1999, Pharmacological reviews.

[5]  B. Maigret,et al.  Arginine 336 and Asparagine 333 of the Human Cholecystokinin-A Receptor Binding Site Interact with the Penultimate Aspartic Acid and the C-terminal Amide of Cholecystokinin* , 1999, The Journal of Biological Chemistry.

[6]  B. Roques,et al.  CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology , 1999, Progress in Neurobiology.

[7]  F Noble,et al.  The CholecystokininB Receptor Is Coupled to Two Effector Pathways Through Pertussis Toxin‐Sensitive and ‐Insensitive G Proteins , 1999, Journal of neurochemistry.

[8]  H. Simon,et al.  Opposing effects of two CCKB agonists on the retrieval phase of a two-trial memory task after systemic injection in the rat , 1999, Neuropharmacology.

[9]  I. Léna,et al.  CCK in Anxiety and Cognitive Processes , 1998, Neuroscience & Biobehavioral Reviews.

[10]  B. Roques,et al.  The CCK‐B Agonist, BC264, Increases Dopamine in the Nucleus Accumbens and Facilitates Motivation and Attention After lntraperitoneal Injection in Rats , 1997, The European journal of neuroscience.

[11]  B. Roques,et al.  The transfer of rats from a familiar to a novel environment prolongs the increase of extracellular dopamine efflux induced by CCK8 in the posterior nucleus accumbens , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[12]  Jacqueline N. Crawley,et al.  Biological actions of cholecystokinin , 1994, Peptides.

[13]  B. Roques,et al.  Heterogeneity of CCK-B receptors involved in animal models of anxiety , 1994, Pharmacology Biochemistry and Behavior.

[14]  W. Dehaen,et al.  Synthesis of thiazolo[4,3-a]isoindoles by intramolecular cycloaddition-elimination reactions of 4-methyl-5-(substituted)imino-Δ2-1,2,3,4-thiatriazolines , 1993 .

[15]  B. Roques,et al.  Synthesis of tritium labelled CCK4 (Trp‐Met‐Asp‐[3H]Phe‐NH2) , 1989 .

[16]  B. Roques,et al.  Enzyme-resistant CCK analogs with high affinities for central receptors , 1988, Peptides.

[17]  B. Roques,et al.  Synthesis of tritium labelled cholecystokinin derivative : [3H]‐Boc‐[Nle28, 31]‐ CCK27–33 , 1985 .

[18]  B. Ganem,et al.  An exceptionally mild deprotection of phthalimides , 1984 .